Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Clinical Pharmadynamics of Evolocumab

Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

The pharmacodynamic effects of PCSK9 inhibitor evolocumab are rapid, with maximum suppression within 4 hours, according to a recent review of the clinical pharmacokinetics and pharmacodynamics. The review also found:

  • Evolocumab exhibits nonlinear kinetics and a half-life of 11 to 17 days.
  • With maximal suppression of PCSK9 occurring within 4 hours, peak reduction of LDL-C, ranging from 55 to 75%, occurs ~1-2 weeks after a dose of evolocumab.
  • Patient-specific factors do not have a clinically meaningful effect on the pharmacodynamic effects of evolocumab; thus, no dose adjustment is necessary based on patient-specific factors of concomitant medication use.
  • When combined with a statin, evolocumab can result in additional lowering of LDL-C.


Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. [Published online ahead of print January 20, 2018]. Clin Pharmacokinet. doi:10.1007/s40262-017-0620-7.

This Week's Must Reads

Improving CV Health in Women Through Provider Collaboration, Circulation; ePub 2018 May 10; Brown, et al

Burden of AF With Risk of Stroke in Paroxysmal AF, JAMA Cardiol; ePub 2018 May 16; Go, et al

OSA & Risk of Hospitalization in Patients with HFpEF, Am J Cardiol; ePub 2018 May 11; Abdullah, et al

Air Pollution Exposure in Pregnancy & Risk of High BP, Hypertension; ePub 2018 May 14; Zhang, et al

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

Must Reads in Hypercholesterolemia

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

PCSK9 Inhibitors for Tx of Hypercholesterolemia, Ann Pharmacother; ePub 2018 Apr 1; Patel, et al

High-Intensity Statin Use and LDL-C Control, J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al

Improving Adherence with ASCVD Interventions, Clin Cardiol; ePub 2018 Apr 17; Fentanes, et al

Lipid Screening in Children with NAFLD, J Pediatr; ePub 2018 Apr 13; Harlow, et al